scispace - formally typeset
A

Anna L. Goodman

Researcher at University College London

Publications -  31
Citations -  4081

Anna L. Goodman is an academic researcher from University College London. The author has contributed to research in topics: Plasmodium falciparum & Antigen. The author has an hindex of 22, co-authored 31 publications receiving 3073 citations. Previous affiliations of Anna L. Goodman include Royal Free London NHS Foundation Trust & Northwick Park Hospital.

Papers
More filters
Journal ArticleDOI

Erratum: Corrigendum: The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody

TL;DR: In the Methods section of this Article, the species of the tissue plasminogen activator secretory signal used in adenovirus vector construction was stated incorrectly and should have been given as human.
Journal ArticleDOI

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

Katherine R. W. Emary, +69 more
- 10 Apr 2021 - 
TL;DR: A post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against B.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020 as discussed by the authors.
Journal ArticleDOI

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Alasdair Munro, +314 more
- 02 Dec 2021 - 
TL;DR: The COV-BOOST trial as mentioned in this paper investigated the reactogenicity and immunogenicity of seven different COVID-19 vaccines as a third dose after two doses of ChAdOx1 nCov-19 (Oxford-AstraZeneca; hereafter referred to as ChAd) or BNT162b2 (Pfizer-BioNtech, hearafter referred to As BNT).